Select Your Region
Americas
Europe
Africa
Global
Find participating medical centers and current study status in each of them
Find participating medical centers
-
Home
-
Clinical Study Finder
- Clinical Study Details
An Observational Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
Cancer Tumor Neoplasms Fallopian Tube Neoplasms Ovarian Neoplasms Peritoneal Neoplasms Ovarian Cancer
- For Medical Professional
-
Download -
Basic Details
Sponsor
Hoffmann-La Roche
Study Identifier
NCT01932125, ML28446
Condition
Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms
Official Title
An Indian Multicentric, Open Label, Prospective Phase 4 Study of Bevacizumab in the Front Line Management of Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer in Real-life Clinical Practice
Study Summary
This multicenter prospective study will evaluate the safety and efficacy of Avastin (bevacizumab) in routine clinical practice in patients with advanced/metastatic epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer. Data will be collected from eligible patients until death, withdrawal of consent, loss to follow-up, or study closure.
Eligibility Criteria
Female
≥ 18 Years
No
Inclusion Criteria
- Prescribed to receive bevacizumab or already ongoing on treatment with bevacizumab for advanced/metastatic ovarian cancer, fallopian tube cancer or primary peritoneal cancer (FIGO Stage IIIb, IIIc and IV) according to routine clinical practice
Exclusion Criteria
- Not eligible for treatment with bevacizumab according to the local prescribing information
This page summarises information from public registry websites, such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. To learn more about this study, see the For Medical Professional tab or visit one of those websites.
The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.
Results Disclaimer
Explore related studies
For the latest version of this information please go to www.forpatients.roche.com